Tetrabenazine [99] (Table 2), and its variants deutetrabenazine and valbenazine are also VMAT2 inhibitors that have been approved by the FDA for treating TD [100,101], but efforts continue to develop better VMAT2 inhibitors. This evidence concerns the gene SLC18A2 and thanatophoric dysplasia.